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Abstract
Metastasis accounts for 90% of cancer-related mortality. Brain metastases generally present during the late stages
in the natural history of cancer progression. Recent advances in cancer treatment and management have resulted
in better control of systemic disease metastatic to organs other than the brain and improved patient survival.
However, patients who experience recurrent disease manifest an increasing number of brain metastases, which are
usually refractory to therapies. To meet the new challenges of controlling brain metastasis, the research community
has been tackling the problem with novel experimental models and research tools, which have led to an improved
understanding of brain metastasis. The time-tested “seed-and-soil” hypothesis of metastasis indicates that successful
outgrowth of deadly metastatic tumors depends on permissible interactions between the metastatic cancer cells
and the site-specific microenvironment in the host organs. Consistently, recent studies indicate that the brain, the
major component of the central nervous system, has unique physiological features that can determine the
outcome of metastatic tumor growth. The current review summarizes recent discoveries on these tumor-brain
interactions, and the potential clinical implications these novel findings could have for the better treatment of
patients with brain metastasis.
Introduction
Brain metastasis is the major cancerous disease in the
central nervous system (CNS), outnumbering primary
brain tumor cases 10-fold [1]. Lung cancer, breast can-
cer and melanoma account for most clinical cases of
brain metastasis from non-CNS primary tumors [2].
Brain metastasis often manifests at late stages of meta-
static disease progression and causes rapid deterioration
in patients’ quality of life including neurocognitive
impairment [3], although latency varies among different
tumor types and many small cell lung cancer patients
already exhibit metastatic lesions in the CNS at the time
of primary tumor diagnosis. Distinct tumor cell proper-
ties from different primary organ sites are likely critical
factors responsible for the discrepancy in brain metasta-
sis latency, though the exact molecular mechanism
remains elusive. With advances in cancer treatments
that better control systemic metastatic diseases at other
organ sites, more brain metastasis has emerged in the
clinic as exemplified in the cases of HER2-positive
breast cancer patients treated by the monoclonal anti-
body trastuzumab (Herceptin). More than one-third of
trastuzumab-treated patients developed brain metastasis
in clinical trials [4-6]. Brain metastatic tumors are gen-
erally refractory to conventional chemotherapy and the
recently developed targeted therapeutic regimens, pre-
sumably due to the inability of these therapeutic agents
to penetrate the blood-brain barrier (BBB). Current
standard treatments for brain metastasis include surgical
resection, whole brain radiation therapy (WBRT) or
more focused radio-surgical procedures for small num-
bers of tumor lesions in the CNS [7]. Brain metastasis
presents an emerging and urgent unmet medical need
and that has been historically understudied. Recently,
there has been a steady increase of reports in the litera-
ture studying brain metastasis from various primary
tumor sites of origin. The current review will emphasize
the unique challenges posed by brain metastasis and the
latest developments in the field.
I. Brain Metastasis Models
The metastatic process is a multi-step cascade that
requires the completion of a series of highly complex
biological functions by tumor cells, including local inva-
sion of the basement membrane, intravasation into the
blood vessels, survival in the circulation, extravasation
into the target organ tissue and successful colonization
in the distant metastatic site [8]. Disruption of any one
of these steps would abolish the metastatic process.
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tem is essential for the study of metastasis. A conven-
tional experimental metastasis assay uses in vivo tail
vein injection to achieve hematogenous delivery of
tumor cells. However, most tumor cells injected in this
way are trapped in the lungs, as they are the first organ
encountered with an extensive capillary bed. While large
numbers of lung metastases can be reliably produced by
tail vein injection, overt brain metastases were rarely
developed in these models, partially due to the fact that
animals with lung metastases do not survive long
enough for brain metastasis to emerge. Alternatively,
two other in vivo injection routes were developed to
produce experimental brain metastasis, both of which
target the brain as the first capillary bed that injected
tumor cells reach [9]. Direct injection of tumor cells
into the left cardiac ventricle is technically easy to per-
form; the difficulty lies in reliably controlling the exact
number of injected tumor cells due to the necessity of
maintaining the needle tip steady in a beating heart dur-
ing the entire injection. Intra-carotid artery injection of
tumor cells requires highly sophisticated microsurgical
skills but produces experimental results of smaller
variation.
Highly organ-specific tumor cell variants, including
brain-seeking cell lines, can be selected after repeated
application of in vivo injections [10,11]. Of particular note,
a subline of spontaneous brain metastasis was recently
established from in vivo recycling of a human melanoma
cell line WM239A by subcutaneous implantation and sub-
sequent resection of the primary tumors [12].
The spontaneous metastasis model has the advantage
of recapitulating all the important steps of the entire
metastatic cascade, providing a unique platform to dis-
sect the molecular mechanisms underlying all of the
individual steps of metastasis. Though various human
tumor cell lines of different origin have been used to
establish brain metastasis mouse models, the pattern of
experimental brain metastasis does not seem to reflect
the discrepancy of metastasis latency that is observed in
t h ec l i n i c .I ns p i t eo ft h i sd e f i c i e n c y ,t h en e w l ye s t a b -
lished murine models are extremely helpful in dissecting
the pathobiology of brain metastasis.
II. Seed and Soil Hypothesis of Metastasis and the
Brain Microenvironment
In 1889, after carefully examining more than 700 cases
of breast cancer patients, British surgeon Stephen Paget
postulated that cancer metastasis is not a random event
and that successful metastatic tumor growth requires
compatible interaction between the tumor cells (“seed”)
and the distant organ tissues to which tumors metasta-
size ("soil”) [13]. In the following 120 years, numerous
clinical observations and scientific experiments support
the “seed-and-soil” hypothesis, which has become the
conceptual foundation for modern studies of cancer
metastasis. It is no exception for brain metastasis:
unique factors in the brain microenvironment can deter-
mine its interaction with metastatic tumor cells and the
eventual outgrowth of metastatic tumor lesions.
The brain is the most complex organ, both structu-
rally and physiologically, in the human body, and the
site where the majority of CNS functions are performed.
There are two major cell types in the brain, neurons
and glial cells (astroglia, microglia, oligodendroglia and
satellite cells). From a cellular standpoint, the brain is
also the most heterogeneous organ in the body since no
two neurons are the same and various glial cells serve
drastically different functions to maintain brain homeos-
tasis and support neuronal functions. In addition to the
parenchymal tissue where all of the neurons and glial
cells reside, the brain ventricles form a contiguous com-
partment with the leptomeningeal space that separates
the parenchymal tissue and the skull. Cerebral-spinal
fluid (CSF) is produced in the ventricles and flows in
this compartment to create a buffer for the entire brain.
The leptomeningeal space represents a distinct microen-
vironment within the CNS and is often another pre-
ferred site for clinically-presenting tumor metastasis
[14]. However, very few studies have been reported in
literature to investigate tumor metastasis to this com-
partment [15,16], largely due to the lack of appropriate
animal models that reflect clinical observations. This
review focuses on the microenvironment determinants
in the brain parenchyma.
The brain’s interaction with metastatic tumor cells lar-
gely stems from three unique properties, which include
the presence of blood-brain/tumor barriers, large nutri-
ent supply and energy consumption, and its status as a
site of immune privilege. Metastatic cells take advantage
of these properties for their successful growth in the
brain. Recent progress from different fields has shed
new light on each of these brain functions and their
relationship to metastatic tumor outgrowth.
III. Blood-Brain/Tumor Barrier and Vascular
Re-modeling
The brain has the highest vascular density among all
organs, yet the brain endothelia form tight junctions
that separate the brain parenchyma from the body’s gen-
eral blood circulation. The circulating small molecules
and cells that are easily permeable through the blood
vessel wall in other organs are usually prevented from
entering the brain parenchyma through the brain
endothelia, thus termed the “blood-brain barrier” (BBB).
It is generally agreed that such an evolutionary outcome
is to protect the brain parenchyma, where essential phy-
siological functions critical for the continuous proper
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ventional chemotherapeutic or targeted therapeutic
agents cannot penetrate the BBB, thereby posing a tre-
mendous obstacle to the treatment of brain metastatic
tumors. On the other hand, precisely how tumor cells
are able to penetrate the BBB and gain access to the
brain parenchyma has not been studied. Strictly speak-
ing, once tumor cells have outgrown and developed
their own blood supply, the interface between the blood
vessels within the tumor are termed the “blood-tumor
barrier” and should be considered different from the
BBB. Recently, state-of-the-art imaging technologies have
been used to track isotope-labelled chemotherapeutic
drugs and measure BBB permeability simultaneously
[17]. It was demonstrated that while some tumor-asso-
ciated blood vessels may become leaky in the brain, many
blood-tumor barriers are impermeable to therapeutic
agents used in the study. Furthermore, no significant cor-
relation was observed between the size of the metastatic
tumor and the leakiness of the blood vessels within the
tumor. The study also discovered an unexpectedly high
heterogeneity of the permeabilities of tumor-associated
blood vessels. The clinically important implication is that
the capability to penetrate the BBB will be essential for
any new chemotherapeutic drugs to be successful in
treating brain metastasis [18]. Recently, multiphoton
microscopy has been used to monitor live tumor cells in
the brain for weeks after hematogenous implantation,
thus revealing the vascular remodelling processes during
early-stage tumor cell colonization [19]. In addition to
capturing the live tumor cell extravasation through the
BBB, comparison of a pair of lung cancer cells and mela-
noma cells suggested that the divergent pathways of
either co-opted microvascular remodelling and simulta-
neous growth merely a few days after successful tumor
cell extravasation or the slower growth factor-induced
angiogenic growth accounts for the length of latency in
forming brain metastases. Although the molecular
mechanisms underlying these tumor-vessel interactions
and their resolution with the clinical observations remain
still to be elucidated and determined, the application of
these new technologies should greatly help future investi-
gators study these events in vivo with unprecedented pre-
cision. Adding another twist to the study of these
complex interactions, immunohistochemical (IHC) stain-
ing of surgically resected breast cancer brain metastases
has revealed a more disrupted BBB in brain metastasis
from triple-negative/basal-like breast cancers than that
from HER2-positive breast cancers [20]. In spite of these
exciting studies, the exact molecular mechanisms that
regulate the BBB remain unknown. In a recent pair of
reports in Nature, experiments using transgenic and
knockout mice clearly demonstrated that the pericytes
surrounding the brain blood vessels play an intimate role
in the formation and maintenance of BBB integrity, chal-
lenging the conventional view that astroglial cells play
the major role in regulating the BBB [21,22]. Thus, it
would be interesting to ask whether alterations of the
BBB in brain metastasis are mediated by tumor-pericyte
interactions. Unfortunately, no such studies have been
reported to date.
Even though the brain has a very dense network of
pre-existing vasculature, several groups have reported
that the potent angiogenesis/permeability factor, vascu-
lar endothelial growth factor (VEGF), seems to be neces-
sary for tumor outgrowth in the brain [23,24]. For
example, activation of tumor cell integrin aVb3 controls
brain metastasis through regulation of VEGF expression
[25]. Whether tumor-associated blood vessels are
formed by new vessel formation or by co-option of
existing highly dense vessels may ultimately depend on
the context of the specific interaction of tumor cells
with their immediate microenvironment. Recently, glio-
blastoma stem-like cells were observed to be able to dif-
ferentiate into endothelial cells and provide a blood
supply within tumor lesions [26,27]. Though not directly
linked to brain metastasis, these striking findings may
change the current paradigm of blood vessel formation
in tumors, including those in the brain metastasis set-
tings. These novel findings may also impact the thera-
peutic manipulation of the BBB, which is likely the key
in making current therapeutic agents effective in treat-
ing brain metastasis.
IV. Abundant Nutrient Supply and Elevated
Energy Metabolism
The dense network of blood vessels in the brain pro-
vides it with abundant supply of oxygen and nutrients.
The brain has the highest oxygen and glucose consump-
tion rates in the body, and shows strong positive signals
in whole-body
18F-FDG PET scans under normal phy-
siological states. To elucidate whether this high energy
turnover impacts brain metastasis formation, circulating
tumor cells isolated from a breast cancer patient were
injected to produce experimental brain metastasis [28].
High-throughput proteomic analysis comparing the
brain-seeking variants with the parental cells revealed
that the brain-derived variants adopted a unique meta-
bolic profile characteristic of elevated expression of var-
ious proteins involved in promoting increased energy
utilization. In another study, microarray expression pro-
filing was performed to compare laser-captured tumor
cells from surgically resected human breast cancer brain
metastasis samples. The study revealed that hexokinase
2 (HK2), which mediates the first step in glucose meta-
bolism by phosphorylating glucose to produce glucose-
6-phosphate, is a candidate gene up-regulated in brain
metastasis samples [29]. Interestingly, HK2 expression
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the MDA-MB-231 breast cancer cell line compared with
the parental cells. Further loss-of-function genetic stu-
dies also confirmed that HK2 contributes to the brain
metastasis phenotype.
It was first observed by Nobel laureate Otto Warburg
that most cancer cells rely on an alternative metabolic
strategy through shifting the major output of cellular
metabolism to lactate production even under aerobic
conditions, an observation aptly termed the “Warburg
Effect” [30]. Warburg further postulated that such
changes in metabolism underscore the fundamental
cause of cancer [31]. Since the brain provides the most
abundant nutrient and energy sources in the body, it is
conceivable, but still remains to be tested, that tumors
endowed with higher efficiency in utilizing the existing
metabolic resources would gain an advantage in produ-
cing brain metastasis.
V. Immune-Privileged Sanctuary with Unique
Defensive Mechanisms
The brain is one of the few organs that are separated from
circulating immune cells, partially due to the presence of
the BBB. Though long regarded as an immune-privileged
organ, the brain is not immune deficient. Microglia are a
specialized population of glial cells that are regarded as
the resident macrophages in the brain. Like macrophages,
under proper conditions microglia are phagocytic and able
to present antigens. Using transgenic mice carrying a GFP
reporter protein driven by the CX3CR1 promoter, which
is only active in microglia cells within the brain, two
groups made the same surprising observation that even
under healthy and normal physiological conditions micro-
glia constantly remodel their processes in apparent
attempts to survey the brain parenchymal environment
[32,33], refuting the conventional view that “resting”
microglia are not functionally active.
Astroglial cells, also commonly known as astrocytes,
are another major population of glial cells in the brain.
They carry out house-keeping functions in the brain to
maintain homeostasis and deliver nutrients and energy.
Activation of microglial and astroglial cells are found in
a wide range of brain-related diseases such as neurode-
generative diseases, traumatic injuries and brain tumors,
including both primary and brain metastases. Intensive
activation of glial cells is a prominent feature in both
patients’ brain metastasis tissues and animal models of
the disease [34]. IHC staining indicated that even at the
early stages of the metastatic cascade shortly after
tumor cell extravasation, both microglia and astrocyte
cells are activated, indicating that the surveillance sys-
tem of networked glial cells are very sensitive in detect-
ing microscopic foreign objects such as single metastatic
tumor cells [35]. With this in mind, it is critical to know
how some tumor cells successfully overcome the glial
cell-mediated defensive mechanisms and outgrow to
produce overt macro-metastatic lesions. The interactions
between tumor cells and glial cells in their immediate
microenvironment are poorly studied. One possible
mechanism is that tumor cells secrete immunosuppres-
sive factors that would help overcome the surveillance
by the glial cells [16]. Brain tissue-conditioned medium
can also promote growth and soft agar colony formation
of brain-seeking variant cells but not the parental cells
[34]. Interestingly, astrocytes were shown to protect
human melanoma cells from apoptosis by sequestering
calcium through physical contact gap junctions in
in vitro co-culture experiments [36]. A similar in vitro
experiment indicated that human lung cancer cells and
co-cultured mouse astrocytes can engage in a mutual
stimulation to promote proliferation, likely through
paracrine cytokine signaling [37]. Along this line, tumor
cell expression of neurotrophins, a family of proteins
involved in neuronal survival and development,
was shown to play an important role in promoting mel-
anoma brain metastasis by up-regulating the ECM-
degradative enzymes such as heparanase [38].
Although the activation of glial cells in various CNS-
related diseases was widely observed, the exact roles
they play in disease progression remain elusive and con-
flicting in the literature. Some studies show that glial
activation has neuroprotective effects, whereas others
argue that they promote disease progression [39]. Simi-
larly, it is not yet clear whether the activation of glial
cells promotes or inhibits brain metastasis in vivo.C o n -
clusive demonstration of the functional roles of the glial
cells must employ novel animal models where the acti-
vation of glial cells can be experimentally manipulated
and monitored.
Conclusions
Brain metastasis has become an increasingly challenging
clinical problem, largely due to the recently improved clin-
ical control of systemic metastatic diseases, exemplified by
the use of trastuzumab (Herceptin) for HER2-positive
breast cancer. Yet the biology of brain metastasis is still
poorly understood. It is encouraging to see more efforts
are beginning to be directed toward the study of brain
metastasis and that an increasing number of new in vivo
models have emerged. It is undisputable that the microen-
vironment cells in the tumor stroma contribute signifi-
cantly to the outgrowth of cancer cells both at the primary
site and in distant metastatic organs. The occurrence of
brain metastasis reflects the culmination of such tumor-
microenvironment interactions. Particularly, the afore-
mentioned specialized physiology of the brain not only
contributes to the colonization of metastatic tumor lesions
but also significantly affects the efficacy and outcome of
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three prominent physiological features of the brain that
may impact the natural history of tumor cells in the brain.
Future clinical interventions to treat patients with brain
metastasis must take into consideration the impact of
these important microenvironmental determinants.
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